H

Hua Medicine
HKEX:2552

Watchlist Manager
Hua Medicine
HKEX:2552
Watchlist
Price: 1.53 HKD 4.79%
Market Cap: 1.5B HKD
Have any thoughts about
Hua Medicine?
Write Note

Hua Medicine
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hua Medicine
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
H
Hua Medicine
HKEX:2552
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
PP&E Gross
ÂĄ3.3B
CAGR 3-Years
-2%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
PP&E Gross
ÂĄ854.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
PP&E Gross
ÂĄ7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
PP&E Gross
ÂĄ3.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
PP&E Gross
ÂĄ534.8m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hua Medicine
Glance View

Market Cap
1.5B HKD
Industry
Pharmaceuticals

Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.

Intrinsic Value
0.34 HKD
Overvaluation 78%
Intrinsic Value
Price
H

See Also

Back to Top